Merck Acquires BioControl Systems

US BioTek Laboratories Acquires RealTime Laboratories

March 19, 2024

Healthcare Services

US BioTek Laboratories, a Pike Street Capital portfolio company, has acquired Dallas-based RealTime Laboratories to expand its diagnostic testing capabilities, specifically mycotoxin and infectious disease testing. The deal broadens the combined organization’s services and geographic footprint while both labs continue operating at their respective locations.

AnaBios Acquires Cell Systems

April 4, 2023

Biotechnology

AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

VION Biosciences Acquires BioAssay Systems

February 5, 2025

Biotechnology

VION Biosciences acquired Hayward, California–based BioAssay Systems in January 2025 as the fourth add-on for its life‑science products platform. The deal adds BioAssay Systems’ enzymatic and high‑throughput assay kits, reagents and analytical services to VION’s proprietary product portfolio to accelerate capability expansion for drug discovery and life‑science research customers.

Biobest Group Acquires BioWorks, Inc.

July 10, 2023

Agriculture

Biobest Group has completed its acquisition of BioWorks, Inc., a Victor, New York-based manufacturer and marketer of biopesticides. The deal expands Biobest's biopesticide portfolio and establishes BioWorks' Victor facility as the group's North American manufacturing and marketing hub for biopesticides.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.